Parker Hughes scientists have
developed a new technology capable of preventing the development of breast cancer in mice. The results from these research studies will be published in two back-to-back papers in the November issue of the prestigious international medical journal Arzneimittelforschung (Drug Research). The technology was developed through the combined use of chemistry biology bioinformatics pharmacology and mathematics. In the studies Parker Hughes scientists found that a novel cytotoxic nucleoside analog Compound 003 [3'-Azidothymidine 5' - [p-Methoxyphenyl methoxyalaninyl phospate] was well tolerated in both mice and rats without toxicity. Most notably Compound 003 prolonged cancer-free survival in transgenic mice which otherwise invariably develop HER2 positive metastatic breast cancer without any significant side effects and at dose levels much lower than those found to be safe in animals. |
All times are GMT -7. The time now is 11:12 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021